Vayarin

Omega-3 Polyunsaturated Fatty Acids

Method of action: Lipid Modifying Agents

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vayarin

Quick Facts

Property	Description
Active core	Lipirinen (Proprietary Phosphatidylserine-Omega-3 complex)
Form	Oral Capsule
Pharmacological class	Medical Food (Prescription status)
General purpose	Targeted nutritional support for lipid imbalances
Target Audience	Children and Adolescents

What Type of Product is Vayarin?

Vayarin is classified as a Medical Food, a category that distinguishes it from both conventional pharmaceuticals and general dietary supplements. The designation of Medical Food confirms the product is specially formulated for the clinical dietary management of a disease or condition where specific nutritional requirements are medically established. This classification mandated its administration under medical supervision. Its positioning as a non-drug, non-supplement option for addressing lipid imbalances was its primary differentiating factor. The product is supplied in an oral capsule format, designed for oral intake.

Core Composition: Lipirinen and Phosphatidylserine-Omega-3

The active core of Vayarin is Lipirinen, a proprietary lipid composition featuring Phosphatidylserine-Omega-3 (PS-Omega-3). This unique formulation is a complex combining the phospholipid phosphatidylserine (PS) with long-chain polyunsaturated fatty acids (LC-PUFA), notably enriched with eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA). The components used to create this highly targeted structural composition are typically derived from natural sources, such as marine lipids. The phosphatidylserine component is an essential endogenous substance found in neuronal membranes. The specialized ratio and structure of the EPA-enriched lipids were designed to optimize nutritional delivery to the central nervous system.

General Purpose of the Lipid Formulation

The general purpose of Vayarin is to provide targeted nutritional support by addressing distinct complex lipid imbalances associated with certain neurodevelopmental conditions. By delivering these essential phospholipids and fatty acids, the formulation helps maintain the integrity and functionality of neuronal membranes. This type of lipid composition is intended to influence neuronal activation in areas of the brain governing executive functions. This nutritional restoration approach is designed to optimize the underlying biochemical environment of nerve cells, thereby assisting in the management of the condition by supporting essential brain health functions.

What side effects are possible with Vayarin?

Adverse Reaction Scope

The officially documented safety profile of Vayarin is defined by adverse reactions classified by frequency and system-organ class, as reported in regulatory-aligned summaries from clinical trials. The most common category of reported adverse events is associated with the gastrointestinal system.

Common Adverse Reactions (1% to 10%):

The most frequent events reported in regulatory summaries include gastrointestinal disorders (such as abdominal pain, nausea, dyspepsia, eructation, and vomiting), rashes, infection, general pain, back pain, and taste perversion. The frequency classification indicates these events are seen in up to one in ten users.

System-Organ Classes Involved:

Adverse effects are primarily classified into Gastrointestinal disorders, Skin and subcutaneous tissue disorders, Nervous system disorders (e.g., headache, hyperactivity), and Psychiatric disorders (e.g., tics, insomnia).

Serious Adverse Reactions:

Regulatory safety information notes the occurrence of certain rare but clinically significant reactions. These include anaphylactic reaction (a severe hypersensitivity response) and reports of gastrointestinal hemorrhage.

Safety Restrictions and Population Considerations

Contraindications and Safety Limitations:

Vayarin is formally contraindicated for any individual with a known hypersensitivity to the product or any of its components. Due to the presence of marine-derived ingredients, the safety label specifies that the product should be used with particular caution in patients with a known shellfish allergy.

Population-Specific Safety:

Safety and effectiveness have not been established in pregnant or lactating patients; therefore, use is generally not recommended for these populations according to the official documentation. The regulatory text also states that the safety and effectiveness in pediatric patients have not been formally established. Additionally, the label notes the product may interact with anticholinergic and cholinergic medications.

Overdose and Emergency Response

The official regulatory profile for Vayarin (Lipirinen), a prescription Medical Food, provides guidance on necessary actions following suspected over-ingestion. This profile is distinct from standard pharmaceuticals, as specific toxicological details regarding over-ingestion are generally not documented in the official regulatory prescribing information.

Category	Regulatory Status
Documented Overdose Presentations	No specific symptoms, signs, or clinical changes resulting from over-ingestion are formally detailed in the official regulatory prescribing information.
Severe Outcomes	Life-threatening or serious complications are not officially documented in the overdose section.
Antidote Information	No specific antidote is known for Vayarin, as stated in the official regulatory profile.
Management Strategy	Overdose management is officially constrained to symptomatic and supportive treatment.

When to Seek Immediate Medical Help

The official regulatory mandate is clear for any case of over-ingestion. Immediate medical attention must be sought following any known or suspected over-ingestion of the product. The regulatory profile also mandates contacting a poison control center immediately for expert guidance and assessment. This standard requirement reflects the necessity for professional evaluation and clinical observation, as the official label does not specify the expected clinical course or differential management for this population (children and adolescents). This approach is consistent with the product's regulatory status, limiting management to monitoring and supportive care.

Therapeutic Uses of Vayarin

What Vayarin Treats: Main Uses and Benefits

Vayarin (Lipirinen) is commonly used for the clinical dietary management of symptoms associated with Attention Deficit Hyperactivity Disorder (ADHD) in children and adolescents. The application of this medical food occurs across domains where additional symptomatic support is needed by individuals with conditions characterized by periods of heightened symptoms.

Vayarin is relevant for easing core symptom clusters that interfere with daily functioning. It helps address difficulties related to inattention, sustained focus, and pronounced hyperactive or impulsive behaviors, and is relevant for easing emotional dysregulation. The product supports the patient during difficult episodes by contributing to improved comfort during symptomatic periods.

“This medical food is applied when appropriate for conditions presenting with symptoms that create noticeable functional strain.”

It may assist with maintaining a sense of stability when symptoms are more noticeable, such as during phases where daily activities become temporarily overwhelming.

Quick Fact
Supportive Focus	Assistance with symptomatic management of behavioral and attention symptoms

Regulatory References

NIH Clinical Trials Registry listing

Eligibility and Restrictions for Use

Population Eligibility Rules for Vayarin

The eligibility for Vayarin is defined by official regulatory documents based on the intended target population and specific medical exclusions, considering its classification as a prescription Medical Food.

Approved Age Groups

Vayarin is primarily indicated for children and adolescents for the clinical dietary management of complex lipid imbalances associated with ADHD. While the standard formulation is typically for younger age groups, an extra-strength version was also available for older adolescents and adults with the same medically determined nutritional requirement.

Absolute Prohibitions (Contraindications)

Vayarin is contraindicated in patients with a known hypersensitivity or allergy to the product itself or any of its active components, which include the proprietary phosphatidylserine-omega-3 complex (Lipirinen).

Use Restrictions and Limitations

Population Group	Eligibility Status	Basis for Restriction
Pregnant Patients	Not Recommended	Safety and effectiveness have not been established in this population.
Lactating Patients	Not Recommended	Safety and effectiveness have not been established.
Shellfish Allergy	Use with Caution	The formulation contains shellfish (Krill).
Organ Dysfunction	Conditional Use	Caution is advised for patients with pre-existing conditions like liver disease or arrhythmias.
Infants	Use Not Established	Safety and effectiveness have not been fully established in all pediatric patients, particularly infants.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory documents for this product focus the interaction profile on two specific pharmacological drug categories. There are no detailed pharmacokinetic statements, such as those related to CYP enzyme or transporter modulation, explicitly provided in the regulatory labeling.

Interaction Classification	Relevant Medicinal Product Categories
Pharmacodynamic Concern	Anticholinergic medications
Pharmacodynamic Concern	Cholinergic medications

Interaction Scope and Constraints

The primary official statements indicate that this product may interact with both anticholinergic and cholinergic drugs. This suggests a potential for altered effects, either through potentiation or antagonism, depending on the specific agent co-administered.

Medicinal Product Categories: The documented interaction information identifies only the class of anticholinergic medications and the class of cholinergic medications as relevant interacting agents.
Specific Restrictions: The regulatory information does not list any explicit contraindications or formal procedural rules requiring time separation for administration with food, alcohol, or other products.
Population-Specific Notes: No specific warnings or adjustments related to interactions are provided exclusively for patient populations such as those with hepatic or renal impairment in the current official interaction documentation.

This structure reflects the limited scope of the product’s officially documented interaction profile, defining areas of potential pharmacological influence without quantifying the severity or detailing the underlying mechanisms in the label text.

Mechanism of Action

How Vayarin Works

Vayarin's mechanism of action is rooted in its role as a targeted, essential structural lipid. It operates by providing a proprietary composition of Phosphatidylserine-Omega-3 (PS-Omega-3), which is an essential constituent of nerve cell membranes.

Modulating Neuronal Membrane Integrity

This mechanism focuses on the structural function of the components. PS-Omega-3 is incorporated into the lipid bilayer of neuronal cell membranes, supporting the physical integrity, fluidity, and electrical properties required for signal transduction and synaptic function. Modification of membrane composition by PS-Omega-3 influences the regulation of biological processes dependent on cellular architecture.

Influencing Key Signal Transduction Pathways

The structural action directly impacts functional pathways. The presence of PS-Omega-3 modulates the function of membrane-bound regulatory proteins and enzymes, such as Protein Kinase C (PKC). This process operates within signal transduction pathways, influencing cascades that control cellular excitability and responsiveness.

Impacting Neurotransmitter Dynamics

The integrated structural and functional effects relate to overall physiological processes. The membrane environment, altered by PS-Omega-3, influences the efficient release and reuptake of key neurotransmitters, including dopamine and acetylcholine. The mechanism influences the activity balance within defined neural circuits and may impact the resultant patterns of physiological activity.

Dosage and Administration Information

How Vayarin is Used: Official Administration Guidelines

Vayarin (Lipirinen) is used according to specific administration guidelines established for a Prescription Medical Food. Its usage protocol is focused on providing targeted nutritional support as part of the dietary management of complex lipid imbalances in the patient population.

Administration Scope

The usage instructions define the oral route of administration, consistent with the product being supplied as an oral capsule.

Administration Detail	Official Instruction/Pattern
Route of Administration	Oral
Standard Daily Dosing	Two capsules per day
Frequency	Once daily
Target Age Group	Children and Adolescents
Special Condition	Must be administered under physician supervision

Procedural Structure

The official usage dictates a straightforward oral administration schedule. The standard regimen is defined as two capsules, to be taken once daily. This established pattern of consistent daily intake reflects the product's role in providing long-term clinical dietary management rather than acute treatment cycles. A primary constraint on the administration of Vayarin is the requirement for the patient to be under the supervision of a physician, which frames the entire use protocol due to its status as a Medical Food.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Vayarin

Evidence for Use in Attention Deficit Hyperactivity Disorder (ADHD)

Vayarin was evaluated in research exploring the clinical dietary role in conditions associated with Attention Deficit Hyperactivity Disorder (ADHD) primarily in children and adolescents. The main body of research includes short-term (e.g., 12-week), double-blind, placebo-controlled Randomized Controlled Trials (RCTs). Researchers examined outcomes related to core ADHD symptoms, specifically inattention and hyperactivity/impulsivity, by monitoring patient scores on standard rating scales.

The research so far suggests that findings were mixed across the main study populations. Some key trials reported that measurements of symptom change for the overall group did not reliably distinguish the product from the placebo when analyzing the main endpoint. However, further analysis of the data described measurements related to changes in symptom scores in specific subgroups, such as those with the Inattentive Subtype of ADHD. These findings describe patterns observed in the studies but study results reflect the specific conditions under which they were conducted and describe group patterns, not personal outcomes.

Studies on Associated Symptom Clusters

Beyond core ADHD symptoms, Vayarin was evaluated in studies examining associated symptom clusters, particularly emotional dysregulation, sleep quality, and academic function. This research primarily involved retrospective chart reviews and secondary analyses of existing trial data, rather than dedicated, prospective RCTs where these symptoms were the main focus. This type of research is used in observational settings evaluating daily-life functioning and is applied in studies examining patient-reported experiences.

The findings derived from these observational settings describe patterns observed in the studies where parents or clinicians reported measurements related to these associated challenges. Because this evidence is derived from retrospective and observational sources, certainty remains low compared to controlled trials. This research provides context but not individual predictions regarding outcomes reflecting daily functioning or activity level.

Study Durations and Long-Term Follow-up

The main RCTs were observed in study participants for relatively short periods, typically 12 weeks, with some extensions up to 24 weeks. Regarding extended use, data are still emerging and are mostly collected through retrospective analyses of patient medical records. Therefore, there is limited information for long-term outcomes and the durability of any patterns measured are not fully established.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Vayarin (FAQ)

Q: Is Vayarin a stimulant medication?

According to regulatory documents, Vayarin is classified as a Prescription Medical Food. This designation fundamentally separates it from conventional pharmaceuticals, including stimulant medications. Its purpose is to provide targeted nutritional support rather than acting as a drug.

Q: How long does it usually take to see results from Vayarin?

Clinical trials observed that measurable changes in symptoms, when present, could take up to 12 weeks in some study participants. This information describes patterns observed in groups, not personal results. The research reflects that individual outcomes may vary.

Q: Is it true that Vayarin contains fish oil, and if so, how much?

The active core is a specific composition of Phosphatidylserine-Omega-3 derived from marine lipids, which includes sources like krill. While this is not pure fish oil, the official label notes that the final product may contain fish. The specific concentration of the total fish oil component is not provided in the regulatory information.

Q: Are there any known interactions between Vayarin and common allergy medicines?

Official regulatory documents indicate that the product may interact with medicinal products classified as Anticholinergic medications. Certain common over-the-counter allergy medicines, such as some antihistamines, can belong to this class of agents.

Q: Is Vayarin approved by the FDA?

Vayarin is classified by the U.S. Food and Drug Administration (FDA) as a Prescription Medical Food. This classification confirms that the product is specially formulated to provide targeted nutritional support for the dietary management of a specific condition. This classification under the FDA is distinct from the process for pharmaceutical drug approval.

Q: Is Vayarin used for anxiety or just attention issues?

The product's usage is officially indicated for the clinical dietary management of complex lipid imbalances associated with Attention Deficit Hyperactivity Disorder (ADHD). Official documentation does not list anxiety or mood disorders as an indication for use.

Q: Can Vayarin affect your appetite?

Adverse event summaries note that common side effects include gastrointestinal disorders, such as nausea, abdominal pain, and vomiting. Changes to appetite (increase or decrease) are not specifically listed in the official safety information.

Q: Are there any reported interactions with common cold or flu medicines?

According to regulatory information, Vayarin may interact with medicinal products classified as either Anticholinergic or Cholinergic medications. Some over-the-counter cold and flu medicines may contain agents from these pharmacological classes.

Q: Does Vayarin contain any common allergens like gluten or dairy?

Official product information states that the capsules are formulated without common allergens such as sugar, lactose, yeast, or gluten. However, due to marine-derived ingredients (krill), the official label includes a specific caution for patients with a known shellfish allergy.

Q: How does the phosphatidylserine in Vayarin differ from other supplements?

Vayarin is classified as a Prescription Medical Food, which is a separate category from general dietary supplements. The active core is a proprietary Phosphatidylserine-Omega-3 (PS-Omega-3) composition specifically enriched with EPA, designed for targeted nutritional support.

Q: Is there a maximum age limit for using Vayarin?

The product is primarily indicated for children and adolescents; however, formulations have also been available for older adolescents and adults who share the same medical nutritional requirement. Official regulatory documents do not define a specific maximum age limit for its use.

Q: Does Vayarin affect liver function?

Regulatory safety summaries contain a note regarding one adverse event report that measured an abnormal SGOT value (a marker related to liver function). Official caution is also advised for patients with pre-existing conditions such as liver disease.

Q: Is Vayarin suitable for someone who has fish allergies?

Due to the inclusion of marine-derived ingredients (krill), official documents advise caution for those with a known shellfish allergy. The manufacturer's information also notes the product may contain fish, which is an important consideration for individuals with fish allergies.

Q: Does Vayarin have a generic version available?

According to the regulatory summary information, Vayarin is a proprietary lipid composition (Lipirinen). A generic version of this specific product is not listed as being available.

Q: Can Vayarin be used by people with high blood pressure?

Official documents advise caution for patients who have pre-existing cardiovascular conditions, such as arrhythmias (irregular heartbeat). High blood pressure (hypertension) itself is not specifically listed in the regulatory safety restrictions.

Q: What kind of specialist usually recommends Vayarin?

Official use mandates that the product must be administered under the supervision of a physician. Since the indication is for conditions associated with ADHD-related nutritional requirements, the supervision is typically provided by specialists, such as pediatricians, neurologists, or psychiatrists.

How should Vayarin be stored and disposed of?

How to Store and Dispose of Vayarin

The storage of Vayarin capsules must adhere to strict regulatory conditions to ensure product stability. The product requires storage at a controlled room temperature of 25 C (77 F), with temperature variations permitted between 15 C and 30 C (59 F and 86 F). The capsules must be kept in the original container and protected from light and moisture.

Child-Safety and Disposal Rules

All unused and expired Vayarin must be stored out of the reach of children. For disposal, official governmental guidance recommends utilizing an authorized community drug take-back program. If this is not available, the medicine should be mixed with an unappealing substance, placed in a sealed bag, and discarded in the household trash, following standard regulatory procedures.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

USA

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z